Evidence map›Paper›PMID 42870814›Full record

ArticleTranslational lung cancer research2026

Amivantamab plus chemotherapy

Jin-Yuan Shih, Jie Wang, Yongsheng Wang, Jialei Wang, Se-Hoon Lee, Koichi Azuma, Toshiaki Takahashi, Jiunn-Liang Tan, Chien-Chung Lin, Sandip Ganguly and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Jin-Yuan ShihDepartment of Internal Medicine, National Taiwan University Hospital, Taipei City.
Jie WangChinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Yongsheng WangDepartment of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Jialei WangFudan University Shanghai Cancer Center, Shanghai, China.
Se-Hoon LeeSamsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Koichi AzumaKurume University School of Medicine, Kurume, Japan.
Toshiaki TakahashiShizuoka Cancer Center, Nagaizumi, Japan.
Jiunn-Liang TanDepartment of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Chien-Chung LinDepartment of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan.
Sandip GangulyTata Medical Center, Kolkata, India.
Victor Ho-Fun LeeDepartment of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Zeynep Hande TurnaIstanbul University-Cerrahpasa Cerrahpasa Medical Faculty, Istanbul, Turkey.
Richu SharmaArtemis Hospital, Gurugram, Haryana, India.
Yu Jung KimDivision of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
Pei-Ling ChuJohnson & Johnson, Raritan, NJ, USA.
Sujay ShahJohnson & Johnson, Spring House, PA, USA.
Brooke DiorioJohnson & Johnson, Titusville, NJ, USA.
Byoung Chul ChoDivision of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The Phase 3 MARIPOSA-2 study showed that amivantamab, a bispecific antibody with immune cell-directing activity, plus chemotherapy significantly improved progression-free survival (PFS) compared with chemotherapy alone in participants with common epidermal growth factor receptor Methods: Participants were randomised 2:2:1 to amivantamab-lazertinib-chemotherapy, chemotherapy alone, or amivantamab-chemotherapy. The primary endpoint was PFS by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1). Secondary endpoints included objective response rate (ORR), intracranial PFS, and safety. Due to mid-study modifications to the amivantamab-lazertinib-chemotherapy dosing schedule, follow-up of this group is ongoing. We present results for the amivantamab-chemotherapy Results: There were 190 participants in the Asian subgroup, 63 in the amivantamab-chemotherapy group and 127 in the chemotherapy group. At a median follow-up of 9.5 months, median PFS in the amivantamab-chemotherapy arm was 6.8 Conclusions: Amivantamab-chemotherapy demonstrated superior PFS

Indexed as

AmivantamabAsiaepidermal growth factor receptor (EGFR)non-small cell lung cancer (NSCLC)

Identifiers

PMID42870814
PMCPMC13657905

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.